EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLLEG00000017138
Gene Symbol: NFKB1
1 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSLLEG00000030239
Gene Symbol: NFKB2
1 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSLLEG00000021278
Gene Symbol: NR1H2
1 View Cross-references
304 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSLLEG00000013967
Gene Symbol: NR1H4
1 View Cross-references
387 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSLLEG00000028062
Gene Symbol: NR3C1
1 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSLLEG00000021013
Gene Symbol: NOD2
1 View Cross-references
166 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Delta 1

Ensembl ID : ENSLLEG00000002642
Gene Symbol: OPRD1
1 View Cross-references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Kappa 1

Ensembl ID : ENSLLEG00000008954
Gene Symbol: OPRK1
1 View Cross-references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Mu 1

Ensembl ID : ENSLLEG00000022332
Gene Symbol: OPRM1
1 View Cross-references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSLLEG00000023147
Gene Symbol: OPRL1
1 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Oxytocin Receptor

Ensembl ID : ENSLLEG00000019366
Gene Symbol: OXTR
1 View Cross-references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSLLEG00000023263
Gene Symbol: PAK4
1 View Cross-references
166 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).